K
Karen Owens
Researcher at Merck & Co.
Publications - 23
Citations - 623
Karen Owens is an academic researcher from Merck & Co.. The author has contributed to research in topics: ROMK & hERG. The author has an hindex of 14, co-authored 23 publications receiving 593 citations. Previous affiliations of Karen Owens include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Chemical Genetics Define the Roles of p38α and p38β in Acute and Chronic Inflammation
Stephen J. O'Keefe,John S. Mudgett,Susan Cupo,Janey N. Parsons,Nicole A. Chartrain,Catherine E. Fitzgerald,Shiow-Ling Chen,Karen Lowitz,Cordelia Rasa,Denise M. Visco,Silvi Luell,Ester Carballo-Jane,Karen Owens,Dennis M. Zaller +13 more
TL;DR: It is demonstrated conclusively that specific inhibition of the p38α isoform is necessary and sufficient for anti-inflammatory efficacy in vivo.
Journal ArticleDOI
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Craig K. Esser,Robert L. Bugianesi,Charles G. Caldwell,Kevin T. Chapman,Philippe L. Durette,Narindar N. Girotra,Ihor E. Kopka,Thomas J. Lanza,Dorothy Levorse,Malcolm MacCoss,Karen Owens,Mitree M. Ponpipom,Joseph P. Simeone,Richard K. Harrison,Lisa M. Niedzwiecki,Joseph W. Becker,Alice I. Marcy,Melinda G. Axel,Amy J. Christen,Joseph McDonnell,Vernon L. Moore,Julie M. Olszewski,C. A. Saphos,Denise M. Visco,Frank Shen,Adria Colletti,Philip A. Krieter,William K. Hagmann +27 more
TL;DR: Inhibitors that contained halogenated biphenylylethyl residues at P1' proved to be superior in terms of enzyme potency and oral activity with 2(R)-[2-(4'-fluoro-4-biphenylyl)ethyl]-4(S)-n- butyl-1,5-pentane dioic acid 1-(alpha(S-tert-butylglycine methylamide) amide.
Journal ArticleDOI
The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists
William K. Hagmann,Philippe L. Durette,Thomas J. Lanza,Nancy J. Kevin,Stephen E. de Laszlo,Ihor E. Kopka,David N. Young,Plato A. Magriotis,Bing Li,Linus S. Lin,Ginger X. Yang,Theodore M. Kamenecka,Linda L. Chang,Jonathan E. Wilson,Malcolm MacCoss,Sander G. Mills,Gail Van Riper,Ermengilda McCauley,Linda A. Egger,Usha Kidambi,Kathryn A. Lyons,Stella H. Vincent,Ralph A. Stearns,Adria Colletti,Johannes Teffera,Sharon Tong,Judy Fenyk-Melody,Karen Owens,Dorothy Levorse,Philip Kim,John A. Schmidt,Richard A. Mumford +31 more
TL;DR: SAR and pharmacokinetic characterization of this series of sulfonylated dipeptide inhibitors with structural components that when combined in a single hybrid molecule gave a sub-nanomolar inhibitor as a lead for medicinal chemistry are presented.
Journal ArticleDOI
Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans
Xiaoyan Chu,Shian-Jiun Shih,Rachel J. Shaw,Hannes Hentze,Grace Chan,Karen Owens,Shubing Wang,Xiaoxin Cai,Deborah J. Newton,Jose Castro-Perez,Gino Salituro,Jairam Palamanda,Aaron Fernandis,Choon Keow Ng,Andy Liaw,Mary J. Savage,Raymond Evers +16 more
TL;DR: Whether cynomolgus monkeys are a suitable translational model to study OATP1B-mediated DDIs is evaluated and the inhibitory effect of RIF is determined on in vitro transport and pharmacokinetics of rosuvastatin (RSV) and atorvASTatin (ATV).
Journal ArticleDOI
Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases.
Xiaoyan Chu,Zuo Zhang,Jocelyn Yabut,Sarah Beth Horwitz,John Levorse,Xiang-qing Li,Lei Zhu,Harmony Lederman,Rachel Ortiga,John R. Strauss,Xiaofang Li,Karen Owens,Jasminka Dragovic,Thomas F. Vogt,Raymond Evers,Myung K. Shin +15 more
TL;DR: These studies demonstrate that the ZFN-generated Mdr1a(−/−) rat will be a valuable tool for central nervous system drug target validation and determining the role of P-gp in drug absorption and disposition.